
1. Use of a compound of Formula (I):



(I)

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

$\overline{---}$ designates a single or double bond;

x and y can be both a single bond; when x is a double bond, then y is a single bond and R^4 and R^{16} are absent; when y is a double bond, then x is a single bond and R^5 and R^{16} are absent;

R^1 is independently selected from the group consisting of: -CONH(C_{4-18} alkyl), -CONHC_{2-8} haloalkyl, -CONH$(CH_2)_{1-8}$Ph, -CONHCH_2COC_{2-8} alkyl, -$(CH_2)_m$-(C_{3-10} carbocycle substituted with 0-2 R^b and 0-2 R^g), -$(CH_2)_m$-(5- to 6-membered heteroaryl comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^e, O and S; wherein said heteroaryl is substituted with 0-1 R^b and 0-2 R^g), and a C_{1-12} hydrocarbon chain substituted with 0-3 R^a; wherein said hydrocarbon chain may be straight or branched, saturated or unsaturated;

R^2 is independently selected from the group consisting of: C_{1-4} alkyl, C_{3-4} cycloalkyl, and C_{1-4} haloalkyl;

R^3 is independently selected from the group consisting of: H, F, Cl, C_{1-4} alkyl and CN;

R^4 and R^5 are independently selected from the group consisting of: H, F, Cl, and C_{1-4} alkyl;

when x is a single bond, R^3 and R^4 may be combined with the carbon atom to which they are attached to form a 3- to 6-membered carbocycle;

R^6 is independently selected from the group consisting of: H, halo, C_{1-4} alkyl, NO_2, R^c, $-(CH_2)_n-(X)_t-(CH_2)_mR^c$, NH_2, $-CONH(C_{1-6}$ alkyl), $-NHCOX_1SO_2R^j$, $-NHCOCH_2PO(OEt)_2$, $-NHCOCOR^j$, $-NHCOCH(OH)R^j$, $-NHCOCH_2COR^j$, $-NHCONHR^j$, and $-OCONR^fR^j$;

X is independently selected from the group consisting of: O, S, NH, CONH, and NHCO;

X_1 is independently C_{1-4} hydrocarbon chain optionally substituted with C_{1-4} alkyl or C_{3-4} cycloalkyl;

when y is a single bond, R^5 and R^6 may be combined with the carbon atom to which they are attached to form a 3- to 6-membered carbocycle;

R^{11}, R^{12}, R^{13}, R^{14} and R^{15} are independently selected from the group consisting of: H, halo, C_{1-4} alkyl substituted with 0-2 R^i, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, $-(CH_2)_m-C_{3-6}$ cycloalkyl, CN, NR^fR^j, OR^j, SR^j, $NHCO_2(C_{1-4}$ alkyl), $NHSO_2(C_{1-4}$ alkyl), and a 4- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^e, O, and S;

alternatively, R^{11} and R^{12}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR^e, O, and S;

alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR^e, O, and S;

R^{16} is independently selected from the group consisting of: H and C_{1-4} alkyl;

R^a is, at each occurrence, independently selected from the group consisting of: halo, OH, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, $N(C_{1-4}$ alkyl)$_2$, $-(CH_2)_n-(X)_t-(CH_2)_mR^c$, and $-(CH_2)_n-(CH_2O)_m-(CH_2)_nR^f$;

R^b is, at each occurrence, independently selected from the group consisting of: halo, OH, C_{1-10} alkyl, C_{1-10} alkoxy, C_{1-10} haloalkyl, C_{1-10} haloalkoxy, C_{1-10} alkylthio, C_{1-10} haloalkylthio, $N(C_{1-4}$ alkyl)$_2$, $-CONH(CH_2)_{4-20}H$, $-O(CH_2)_sO(C_{1-6}$ alkyl), R^c, $-(CH_2)_n-(X)_t-(CH_2)_mR^c$, and $-(CH_2)_n-(CH_2O)_m-(CH_2)_nR^f$;

R^c is, at each occurrence, independently selected from the group consisting of: C_{3-6} cycloalkyl substituted with 0-2 R^d, C_{3-6} cycloalkenyl substituted with 0-2 R^d, -$(CH_2)_m$-(phenyl substituted with 0-3 R^d), and a 5- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^e, O, and S; wherein said heterocycle is substituted with 0-2 R^d;

R^d is, at each occurrence, independently selected from the group consisting of: halo, OH, CN, NO_2, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, tetrazolyl, OBn and phenyl substituted with 0-2 R^h;

R^e is, at each occurrence, independently selected from the group consisting of: H, C_{1-8} alkyl, C_{1-8} haloalkyl, benzyl optionally substituted with C_{1-4} alkoxy, $CO(C_{1-4}$ alkyl) and COBn;

R^f is, at each occurrence, independently selected from the group consisting of: H and C_{1-4} alkyl;

R^g, R^h and R^i are, at each occurrence, independently selected from the group consisting of: halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

R^j is, at each occurrence, independently selected from the group consisting of: C_{1-4} alkyl, C_{3-4} cycloalkyl and phenyl;


n, at each occurrence, is independently 0 or 1;

m, at each occurrence, is independently 0, 1, 2, 3, or 4

s, at each occurrence, is independently 1, 2, or 3; and

t, at each occurrence, is independently 0 or 1;


provided that the following compound is excluded:



in the manufacture of a medicament for the treatment of diabetes, hyperglycemia, gestational diabetes, obesity, dyslipidemia, hypertension, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, wherein a therapeutically effective amount of said medicament is to be administered to a patient in need thereof.


2. Use of the compound in claim 1,

wherein the compound is of Formula (II), which is a subset of Formula (I):



(II)

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is  ;

R^2 is independently selected from CF_3 and CH_3;

R^3 is independently selected from the group consisting of: H and F;

R^4 is independently selected from the group consisting of: H and F;

R^6 is independently selected from: R^c, -$CONHR^c$, -$NHCOR^c$, and -$NHCOCH_2SO_2(C_{1\text{-}4}$ alkyl);

R^{11} and R^{15} are independently selected from the group consisting of: H, $C_{1\text{-}4}$ alkyl and halo;

R^{12} and R^{14} are independently selected from the group consisting of: H, halo, $C_{1\text{-}4}$ alkyl and $C_{1\text{-}4}$ alkoxy;

R^{13} is independently selected from the group consisting of: H, halo, $C_{1\text{-}4}$ alkyl substituted with 0-1 $C_{1\text{-}4}$ alkoxy, $C_{1\text{-}4}$ alkoxy, $C_{1\text{-}4}$ haloalkyl, $C_{1\text{-}4}$ haloalkoxy, -$(CH_2)_m$-$C_{3\text{-}4}$ cycloalkyl, CN, $N(C_{1\text{-}4}$ alkyl$)_2$, $NHCO_2(C_{1\text{-}4}$ alkyl), $NHSO_2(C_{1\text{-}4}$ alkyl), pyrazolyl, and morpholinyl;

alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR^e, O, and S;

R^b is independently selected from: $-O(CH_2)_{1-6}CF_3$, $-O(CH_2)_{1-4}CF_2CF_3$, $-CONH(CH_2)_{6-20}H$, cyclopent-1-en-1-yl, cyclohex-1-en-1-yl, $-O(CH_2)_2$(cyclopentyl), phenoxy, benzoxy, pyrimidin-5-yl, pyrazin-2-yl and -O-pyrimidin-2-yl;

R^c is, at each occurrence, independently selected from the group consisting of: $-(CH_2)_m$-(phenyl substituted with 0-3 R^d), and a heteroaryl selected from: oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, and pyrazinyl; wherein said heteroaryl is substituted with 0-2 R^d; and

R^d is, at each occurrence, independently selected from the group consisting of: halo, OH, CN, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, tetrazolyl and OBn;

R^g is, at each occurrence, independently selected from the group consisting of: halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

m, at each occurrence, is independently 0, 1, 2 or 3; and

s, at each occurrence, is independently 1, 2, or 3,

in the manufacture of a medicament for the treatment of diabetes, hyperglycemia, gestational diabetes, obesity, dyslipidemia, hypertension, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, wherein a therapeutically effective amount of said medicament is to be administered to a patient in need thereof.

3. Use of the compound in claim 1, wherein the compound is selected from:

(*S*)-3-(1*H*-tetrazol-5-yl)-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-N-(4-methoxyphenyl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-3-(2*H*-tetrazol-5-yl)-4-(p-tolyl)-6-(4-((6,6,6-trifluorohexyl)oxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-N-(4-(trifluoromethoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-N-(6-methoxypyridin-3-yl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-N-cyclopropyl-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-N-(4-hydroxyphenyl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-4-(4-(difluoromethoxy)phenyl)-3-(1*H*-tetrazol-1-yl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-3-methyl-N-(2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)isoxazole-5-carboxamide,

(*S*)-5-methyl-N-(2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide,

N^2-heptyl-N^5-(4-methoxyphenyl)-2-methyl-6-oxo-4-(p-tolyl)-1,2,3,6-tetrahydropyridine-2,5-dicarboxamide,

(*S*)-3-(1*H*-tetrazol-1-yl)-4-(p-tolyl)-6-(4-((6,6,6-trifluorohexyl)oxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-4-(5,6,7,8-tetrahydronaphthalen-2-yl)-3-(1*H*-tetrazol-5-yl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-2-(methylsulfonyl)-N-(2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)acetamide,

(*S*)-3-(1*H*-tetrazol-5-yl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-4-(4-(2,2,2-trifluoroethyl)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one, and


(*S*)-N-(5-methoxypyrazin-2-yl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide;

or a tautomer, or a pharmaceutically acceptable salt thereof,

in the manufacture of a medicament for the treatment of diabetes, hyperglycemia, gestational diabetes, obesity, dyslipidemia, hypertension, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, wherein a therapeutically effective amount of said medicament is to be administered to a patient in need thereof.


4. Use of the compound in claim 1,

wherein the compound is of Formula (II), which is a subset of Formula (I):



(II)

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is independently selected from the group consisting of: $C_{1\text{-}6}$ alkyl, -$CONHC_{4\text{-}18}$ alkyl, -$CONH(CH_2)_{1\text{-}8}Ph$, and 

;

R^2 is independently selected from the group consisting of: $C_{1\text{-}4}$ alkyl and $C_{1\text{-}4}$ haloalkyl;

R^3 is independently selected from the group consisting of: H and F;

R^4 is independently selected from the group consisting of: H and F;

R^6 is independently selected from the group consisting of: NH_2, -$CONH(C_{1\text{-}6}$ alkyl), -$NHCOCH_2PO(OEt)_2$, -$NHCO(CH_2)SO_2(C_{1\text{-}4}$ alkyl), R^c, OR^c, -$CONHR^c$, and -$NHCOR^c$;

R^{11} and R^{15} are independently selected from the group consisting of: H, $C_{1\text{-}4}$ alkyl and halo;

R^{12} is independently selected from the group consisting of: H, halo, $C_{1\text{-}4}$ alkyl and $C_{1\text{-}4}$ alkoxy;

R^{13} is independently selected from the group consisting of: H, halo, $C_{1\text{-}4}$ alkyl substituted with 0-1 $C_{1\text{-}4}$ alkoxy, $C_{1\text{-}4}$ alkoxy, $C_{1\text{-}4}$ haloalkyl, $C_{1\text{-}4}$ haloalkoxy, -$(CH_2)_m$-$C_{3\text{-}4}$ cycloalkyl, CN, $N(C_{1\text{-}4}$ alkyl$)_2$, $NHCO_2(C_{1\text{-}4}$ alkyl), $NHSO_2(C_{1\text{-}4}$ alkyl), pyrazolyl, and morpholinyl;

alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered saturated heterocyclic ring comprising: carbon atoms and 1-2 oxygen atoms;

R^{14} is independently selected from the group consisting of: H and C_{1-4} alkoxy;

R^b is, at each occurrence, independently selected from the group consisting of: halo, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-10} haloalkoxy, $-O(CH_2)_sO(C_{1-6}$ alkyl), $-CONH(CH_2)_{6-20}H$, $-(CH_2)_m(C_{3-6}$ cycloalkyl), $-(CH_2)_m(C_{4-6}$ cycloalkenyl), $-O(CH_2)_m(C_{3-6}$ cycloalkyl), phenoxy, benzoxy, morpholinyl, 2-C_{1-4} alkoxy-pyridin-5-yl, pyrimidin-5-yl, pyrazin-2-yl and -O-pyrimidinyl; and

R^c is, at each occurrence, independently selected from the group consisting of: C_{3-6} cycloalkyl substituted with 0-2 R^d, $-(CH_2)_m$-(phenyl substituted with 0-3 R^d), and a heteroaryl selected from: oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, and pyrazinyl; wherein said heteroaryl is substituted with 0-2 R^d;


R^g is, at each occurrence, independently selected from the group consisting of: halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

m, at each occurrence, is independently 0, 1, 2 or 3; and

s, at each occurrence, is independently 1, 2, or 3,


in the manufacture of a medicament for the treatment of diabetes, hyperglycemia, gestational diabetes, obesity, dyslipidemia, hypertension, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, wherein a therapeutically effective amount of said medicament is to be administered to a patient in need thereof.

5. Use of the compound in claim 1, wherein the compound is of Formula (II), which is a subset of Formula (I):



(II)

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is independently  ;

R^2 is independently selected from the group consisting of: CF_3 and Me;

R^3 is independently selected from the group consisting of: H and F;

R^4 is independently selected from the group consisting of: H and F;

R^6 is independently: 1*H*-imidazol-1-yl, 1*H*-tetrazol-1-yl, 1*H*-tetrazol-3-yl, or 2*H*-tetrazol-5-yl;

R^{11} and R^{15} are independently selected from the group consisting of: H, Me, F, and Cl;

R^{12} is independently selected from the group consisting of: H, F, Cl, Me and OMe;

R^{13} is independently selected from the group consisting of: H, F, Cl, Br, Me, OMe, OEt, CH_2OMe, CF_3, CH_2CF_3, $OCHF_2$, OCF_3, CN, $N(Me)_2$, cyclopropyl and cyclopropylmethyl;

alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered saturated heterocyclic ring comprising: carbon atoms and 1-2 oxygen atoms;

R^{14} is H;

R^b is independently selected from: $-O(CH_2)_{1-6}CF_3$, and $-O(CH_2)_{1-4}CF_2CF_3$;

R^c is, at each occurrence, independently selected from the group consisting of: C_{3-6} cycloalkyl substituted with 0-2 R^d, $-(CH_2)_m$-(phenyl substituted with 0-3 R^d), and a heteroaryl selected from: oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, and pyrazinyl; wherein said heteroaryl is substituted with 0-2 R^d;

R^g is F,

m, at each occurrence, is independently 0, 1, 2 or 3; and

s, at each occurrence, is independently 1, 2, or 3,

in the manufacture of a medicament for the treatment of diabetes, hyperglycemia, gestational diabetes, obesity, dyslipidemia, hypertension, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, wherein a therapeutically effective amount of said medicament is to be administered to a patient in need thereof.

6. Use of the compound in claim 1, wherein the compound is selected from:

(S)-3-(1H-tetrazol-5-yl)-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one,

(S)-3-(2H-tetrazol-5-yl)-4-(p-tolyl)-6-(4-((6,6,6-trifluorohexyl)oxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one,

(S)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-N-(4-(trifluoromethoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,


(S)-4-(4-(difluoromethoxy)phenyl)-3-(1H-tetrazol-1-yl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one, and

(S)-2-(methylsulfonyl)-N-(2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)acetamide;

or a tautomer, or a pharmaceutically acceptable salt thereof,


in the manufacture of a medicament for the treatment of diabetes, hyperglycemia, gestational diabetes, obesity, dyslipidemia, hypertension, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, wherein a therapeutically effective amount of said medicament is to be administered to a patient in need thereof.

7. Use of a racemic mixture of a compound having the following formula, which is a subset of the compound in claim 1:












and its enantiomer, or a tautomer, or a pharmaceutically acceptable salt thereof,
in the manufacture of a medicament for the treatment of diabetes, hyperglycemia, gestational diabetes, obesity, dyslipidemia, hypertension, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, wherein a therapeutically effective amount of said medicament is to be administered to a patient in need thereof.

8. Use of a compound having the following formula, which is a subset of the compound in claim 1:




or a tautomer, or a pharmaceutically acceptable salt thereof,
in the manufacture of a medicament for the treatment of diabetes, hyperglycemia, gestational diabetes, obesity, dyslipidemia, hypertension, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, wherein a therapeutically effective amount of said medicament is to be administered to a patient in need thereof.

9. Use of a compound selected from:


,

,

,

,

,

,

,

, and

,

all of which are subsets of the compound in claim 1, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof,
in the manufacture of a medicament for the treatment of diabetes, hyperglycemia, gestational diabetes, obesity, dyslipidemia, hypertension, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, wherein a therapeutically effective amount of said medicament is to be administered to a patient in need thereof.

10. Use of a compound having the following formula, which is a subset of the compound in claim 1:



,

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof
in the manufacture of a medicament for the treatment of diabetes, hyperglycemia, gestational diabetes, obesity, dyslipidemia, hypertension, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, wherein a therapeutically effective amount of said medicament is to be administered to a patient in need thereof.